Groupama Asset Managment Takes Position in Cencora, Inc. $COR

Groupama Asset Managment acquired a new position in shares of Cencora, Inc. (NYSE:COR) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 2,837 shares of the company’s stock, valued at approximately $891,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Cencora by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock worth $7,976,681,000 after purchasing an additional 221,570 shares in the last quarter. State Street Corp increased its holdings in shares of Cencora by 1.3% during the fourth quarter. State Street Corp now owns 9,305,507 shares of the company’s stock valued at $3,142,935,000 after purchasing an additional 115,191 shares during the period. T. Rowe Price Investment Management Inc. raised its stake in shares of Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after purchasing an additional 4,123,795 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Cencora by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock valued at $1,843,268,000 after purchasing an additional 169,055 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Cencora by 6.5% in the fourth quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company’s stock worth $1,682,859,000 after purchasing an additional 304,760 shares during the period. 97.52% of the stock is owned by institutional investors.

Cencora Stock Up 0.1%

COR stock opened at $312.40 on Friday. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The firm has a market cap of $60.78 billion, a PE ratio of 23.96, a P/E/G ratio of 1.73 and a beta of 0.58. The firm has a 50 day simple moving average of $289.36 and a 200 day simple moving average of $315.60. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter last year, the firm posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts forecast that Cencora, Inc. will post 17.8 earnings per share for the current fiscal year.

Cencora announced that its board has initiated a stock buyback program on Thursday, May 21st that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 3.9% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s management believes its shares are undervalued.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s payout ratio is presently 18.40%.

Insider Activity

In related news, Director Lauren M. Tyler bought 550 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were bought at an average cost of $270.23 per share, with a total value of $148,626.50. Following the completion of the transaction, the director directly owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.38% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

COR has been the subject of a number of recent analyst reports. Wells Fargo & Company decreased their target price on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Barclays decreased their price objective on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a report on Wednesday, June 10th. Bank of America boosted their target price on Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a report on Wednesday, June 24th. Evercore set a $360.00 price target on Cencora in a research note on Wednesday, April 8th. Finally, Morgan Stanley set a $342.00 price objective on Cencora in a research note on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.